Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $61.85, for a total transaction of $432,950.00. Following the completion of the sale, the insider owned 33,377 shares of the company’s stock, valued at approximately $2,064,367.45. The trade was a 17.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Wednesday, April 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $66.12, for a total transaction of $462,840.00.
• On Monday, March 16th, Joana Goncalves sold 7,641 shares of Oruka Therapeutics stock. The stock was sold at an average price of $40.91, for a total transaction of $312,593.31.
• On Tuesday, February 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $32.37, for a total transaction of $226,590.00.

Oruka Therapeutics Trading Down 3.1%

Shares of ORKA traded down $1.97 during mid-day trading on Friday, reaching $61.93. The company’s stock had a trading volume of 1,392,935 shares, compared to its average volume of 2,363,309. Oruka Therapeutics, Inc. has a 52 week low of $9.40 and a 52 week high of $91.00. The company’s fifty day moving average price is $55.17 and its two-hundred day moving average price is $39.33.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. As a group, equities research analysts forecast that Oruka Therapeutics, Inc. will post -2.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ORKA has been the subject of a number of recent research reports. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. Barclays upped their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a report on Monday, April 27th. Stifel Nicolaus upped their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. HC Wainwright upped their price target on shares of Oruka Therapeutics from $75.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, UBS Group upped their price target on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $120.80.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORKA. Goldman Sachs Group Inc. bought a new stake in Oruka Therapeutics during the 1st quarter valued at $2,505,000. JPMorgan Chase & Co. increased its position in Oruka Therapeutics by 567.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after purchasing an additional 13,115 shares during the period. Legal & General Group Plc purchased a new position in Oruka Therapeutics during the 2nd quarter valued at $28,000. Rhumbline Advisers purchased a new position in Oruka Therapeutics during the 2nd quarter valued at $320,000. Finally, New York State Common Retirement Fund purchased a new position in Oruka Therapeutics during the 2nd quarter valued at $96,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.